

Article title: Circulating C-reactive protein levels as a prognostic biomarker in breast cancer across body mass index groups

Journal name: Breast Cancer Research and Treatment

Authors: Holm, J.B. (1,2), Baggesen, E. (2), Cronin-Fenton, D. (2,3), Frystyk J. (4), Bruun, J.M. (2,5), Christiansen, P. (2,6), Borgquist, S. (1,2)

Affiliations:

1: Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

2: Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

3: Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark

4: Department of Endocrinology, Odense University Hospital, Odense, Denmark

5: Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark

6: Department of Plastic and Breast Surgery, Aarhus University Hospital, Aarhus, Denmark

Corresponding author: Jonas Busk Holm, e-mail: jonasbuskholm@oncology.au.dk

Supplementary Table 1. C-reactive protein quartiles in relation to disease-free survival in breast cancer patients including three models in the adjusted analyses

	Person-years	Number of events	Incidence rate per 1000 person-years (95% CI)	Crude hazard ratio (95% CI) (N=2,673)	Model 1 ^a : Adjusted hazard ratio (95% CI) (N=2,604)	Model 2 ^b : Adjusted hazard ratio (95% CI) (N=2,508)	Model 3 ^c : Adjusted hazard ratio (95% CI) (N=2,485)
Q1	3871	70	18.08 (14.30-22.85)	Reference	Reference	Reference	Reference
Q2	3854	83	21.54 (17.37-26.71)	1.19 (0.87-1.64)	1.05 (0.75-1.46)	0.96 (0.68-1.36)	0.97 (0.69-1.37)
Q3	3777	100	26.48 (21.76-32.21)	1.47 (1.08-1.99)	1.36 (0.99-1.88)	1.24 (0.89-1.73)	1.24 (0.89-1.74)
Q4	3460	115	33.24 (27.69-39.90)	1.84 (1.37-2.48)	1.69 (1.21-2.35)	1.65 (1.17-2.32)	1.58 (1.12-2.24)
Total	14962	368 ^d					

Abbreviations: 95% *CI* 95% Confidence interval; *Q1* Quartile 1.

a: Adjusted for age, menopausal state, comorbidities, and BMI. b: Adjusted for age, menopausal state, comorbidities, BMI, histological grade, tumor size, lymph node metastases, HER2 status, estrogen receptor status, and histological classification. c: Adjusted for age, menopausal state, comorbidities, BMI, histological grade, tumor size, lymph node metastases, HER2 status, estrogen receptor status, histological classification, surgery, systemic treatment, and radiotherapy. d: 212 recurrences, 38 contralateral BCs, and 118 deaths.

Supplementary Table 2. C-reactive protein quartiles in relation to disease-free survival in breast cancer patients including three models in the adjusted analyses treating other malignancy as event instead of censoring point

	Person-years	Number of events	Incidence rate per 1000 person-years (95% CI)	Crude hazard ratio (95% CI) (N=2,673)	Model 1 ^a : Adjusted hazard ratio (95% CI) (N=2,604)	Model 2 ^b : Adjusted hazard ratio (95% CI) (N=2,508)	Model 3 ^c : Adjusted hazard ratio (95% CI) (N=2,485)
Q1	3871	93	24.02 (19.60-29.44)	Reference	Reference	Reference	Reference
Q2	3854	116	30.10 (25.09-36.11)	1.25 (0.95-1.65)	1.11 (0.84-1.48)	1.02 (0.77-1.37)	1.02 (0.76-1.37)
Q3	3777	134	35.48 (29.95-42.03)	1.48 (1.14-1.93)	1.35 (1.02-1.78)	1.25 (0.94-1.67)	1.25 (0.94-1.67)
Q4	3460	164	47.40 (40.67-55.24)	1.98 (1.54-2.56)	1.74 (1.31-2.32)	1.72 (1.28-2.29)	1.65 (1.23-2.22)
Total	14962	507 ^d					

Abbreviations: 95% *CI* 95% Confidence interval; *Q1* Quartile 1.

a: Adjusted for age, menopausal state, comorbidities, and BMI. b: Adjusted for age, menopausal state, comorbidities, BMI, histological grade, tumor size, lymph node metastases, HER2 status, estrogen receptor status, and histological classification. c: Adjusted for age, menopausal state, comorbidities, BMI, histological grade, tumor size, lymph node metastases, HER2 status, estrogen receptor status, histological classification, surgery, systemic treatment, and radiotherapy. d: 209 recurrences, 38 contralateral BCs, 146 other malignancies, and 114 deaths.

Supplementary Table 3. C-reactive protein quartiles in relation to overall survival in breast cancer patients_including three models in the adjusted analyses

	Person-years	Number of deaths	Incidence rate per 1000 person-years (95% CI)	Crude hazard ratio (95% CI) (N=2,673)	Model 1 ^a : Adjusted hazard ratio (95% CI) (N=2,604)	Model 2 ^b : Adjusted hazard ratio (95% CI) (N=2,508)	Model 3 ^c : Adjusted hazard ratio (95% CI) (N=2,485)
Q1	4044	39	9.64 (7.05-13.20)	Reference	Reference	Reference	Reference
Q2	4067	67	16.47 (12.97-20.93)	1.71 (1.15-2.54)	1.48 (0.98-2.24)	1.33 (0.87-2.04)	1.33 (0.87-2.04)
Q3	3987	87	21.82 (17.69-26.93)	2.27 (1.56-3.31)	2.09 (1.40-3.12)	1.90 (1.26-2.87)	1.93 (1.27-2.91)
Q4	3705	105	28.34 (23.41-34.31)	2.97 (2.06-4.29)	2.61 (1.74-3.91)	2.50 (1.65-3.79)	2.47 (1.62-3.76)
Total	15803	298					

Abbreviations: 95% *CI* 95% Confidence interval; *Q1* Quartile 1.

a: Adjusted for age, menopausal state, comorbidities, and BMI. b: Adjusted for age, menopausal state, comorbidities, BMI, histological grade, tumor size, lymph node metastases, HER2 status, estrogen receptor status, and histological classification. c: Adjusted for age, menopausal state, comorbidities, BMI, histological grade, tumor size, lymph node metastases, HER2 status, estrogen receptor status, histological classification, surgery, systemic treatment, and radiotherapy.